Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01275 (glucagon)
 26,492 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aminoguanidine (AG) is a potential therapeutic agent for preventing the generation of advanced glycation end products in diabetes mellitus. In this study, the effects of AG on glucagon and insulin secretion in in vitro rat pancreatic islets were investigated. The islets were aseptically isolated and cultured in tissue culture medium 199 for 48 h with or without 9.1 mM AG (1 mg/ml). After the culture, 50 islets were perifused in Krebs-Ringer bicarbonate buffer containing 20 mM arginine or 1 U/ml pancreozymin in the presence of 3.3 mM glucose. Islets previous exposed to AG showed similar glucagon response to control islets at a 20 mM arginine concentration, and insulin response, too. Glucagon release caused by 1 U/ml pancreozymin from the islets previously exposed to AG was also not different from that of the control islets, but the release of insulin was much lower than that of control. These results suggest that AG would not be toxic to alpha-cells but toxic to beta-cells at high concentrations, although there is slightly different sensitivity to beta-cell secretagogues.
 ...
PMID:Effects of aminoguanidine on glucagon and insulin release from rat pancreatic islet. 907 14